Viiv’s Cabotegravir Shows Superiority Over Truvada as PrEP Among Women
Executive Summary
ViiV unblinded the Phase III study on positive data, and it plans to pursue approval in H1 2021.
You may also be interested in...
ViiV Readies Entry To HIV PrEP Market After Apretude Approval
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
ViiV Looks Ahead With Third-Gen Integrase Inhibitor From Shionogi
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.
ViiV Aims To Extend HIV Drug Durations With Halozyme’s Technology
ViiV Healthcare’s head of R&D tells Scrip that extending the durations of its long acting HIV treatments is possible using drug delivery technology from Halozyme Therapeutics to expand the body’s capacity to absorb injected medicines.